Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Ozanimod

SKU: orb1226580

Description

Ozanimod (RPC-1063) is a potent, selective agonist of S1P1 and S1P5 receptor with EC50 of 0.41 nM and 11 nM respectively; less potent for S1P2, S1P3 and S1P4 (EC50> 10 uM); induces S1P1 receptor internalization and induced a reversible reduction in circulating B and CCR7(+) T lymphocytes in vivo; shows high oral bioavailability and volume of distribution, and a circulatory half-life.Multiple Sclerosis Phase 3 Clinical(In Vitro):Ozanimod (RPC-1063) has potency and intrinsic activity of S1P receptor modulators for S1P5 across species with [35S]-GTPgS binding, and the EC50 values of 1.03 nM, 1.29 nM, 0.90 nM, 1.02 nM and 0.61 nM for Human S1P1, Cynomolgus monkey S1P1, Mouse S1P1, Rat S1P1 and Canine S1P1, respectively; and the EC50 values of 8.6 nM, 15.9 nM, 957.5 nM, 2032.7 nM and 1662.0 nM for Human S1P5, Cynomolgus monkey S1P5, Mouse S1P5, Rat S1P5 and Canine S1P5, respectively.Ozanimod restores the potency with EC50 from 958 nM for mS1P5 to 6.7 nM for mS1P5_A120T to closely mirror the EC50 for hS1P5 of 8.6 nM by mutating the alanine in the mouse sequence.Ozanimod has binding affinity with Ki values of 2.0 nM, 59.9 nM and 5.6 nM for hS1P5, mS1P5 and mS1P5 _A120T, respectively.Ozanimod has saturation binding of [3H]-ozanimod to hS1P5, and mS1P5_A120T with KD values of 6.56 nM, 7.35 nM, respectively and also has saturation binding for [3H]-A971432 to S1P5D value of 8.75 nM.(In Vivo):Ozanimod (RPC-1063) (oral gavage; 0.05, 0.2, or 1 mg/kg; once daily; for 14 consecutive days) exposures sufficient to engage S1P1, but not S1P5, resulted in reduced circulating lymphocytes, disease scores, and body weight loss; reduced inflammation, demyelination, and apoptotic cell counts in the spinal cord; and reduced circulating levels of the neuronal degeneration marker, neurofilament light.Ozanimod (oral gavage; 5 mg/kg; once-daily) prevented axonal degradation and myelin loss during toxin challenge but did not facilitate enhanced remyelination after intoxication.Ozanimod (oral, 1 or 5 mg/kg, for 7 days) has good pharmacokinetics in mice.

Research Area

Pharmacology & Drug Discovery

Images & Validation

Key Properties

CAS Number1306760-87-1
MW404.4617
Purity>98% (HPLC)
FormulaC23H24N4O3
SMILESN#CC1=CC(C2=NC(C3=CC=CC4=C3CC[C@@H]4NCCO)=NO2)=CC=C1OC(C)C
TargetLysophospholipid Receptor
SolubilityDMSO: ≥ 29 mg/mL

Bioactivity

In Vivo
Ozanimod (RPC-1063) (oral gavage; 0.05, 0.2, or 1 mg/kg; once daily; for 14 consecutive days) exposures sufficient to engage S1P1, but not S1P5, results in reduced circulating lymphocytes, disease scores, and body weight loss; reduces inflammation, demyelination, and apoptotic cell counts in the spinal cord; and reduces circulating levels of the neuronal degeneration marker, neurofilament light. Ozanimod (oral gavage; 5 mg/kg; once daily) prevents axonal degradation and myelin loss during toxin challenge but does not facilitate enhanced remyelination after intoxication. Ozanimod (oral, 1 or 5 mg/kg, for 7 days) has good pharmacokinetics in mice. Animal model: Experimental Autoimmune Encephalomyelitis Model. Dosage: 0.05, 0.2, or 1 mg/kg. Administration: oral gavage; 0.05, 0.2, or 1 mg/kg; once daily; for 14 consecutive days. Result: Attenuated body weight loss, terminal disease scores were significantly attenuated with the 0.2 and 1 mg/kg doses and ALCs were significantly reduced in all dose groups. Reduced spinal cord inflammation and demyelination, as well as attenuated the number of spinal cord apoptotic cells, and significantly reduced the levels of circulating neurofilament light at the top dose of 1 mg/kg. Animal model: Cuprizone/Rapamycin Demyelination Model. Dosage: 5 mg/kg. Administration: oral gavage; 5 mg/kg; once daily. Result: Protected neuronal axons, preventing breakage and ovoid formation in the corpus callosum of CPZ/Rapa treated mice. Significantly attenuated the extent to which the corpus callosum demonstrated reduced myelin content as visualized by MRI.
In Vitro
Ozanimod (RPC-1063) has potency and intrinsic activity of S1P receptor modulators for S1P5 across species with [35S]-GTPgS binding, and the EC50 values of 1.03 nM, 1.29 nM, 0.90 nM, 1.02 nM and 0.61 nM for Human S1P1, Cynomolgus monkey S1P1, Mouse S1P1, Rat S1P1 and Canine S1P1, respectively; and the EC50 values of 8.6 nM, 15.9 nM, 957.5 nM, 2032.7 nM and 1662.0 nM for Human S1P5, Cynomolgus monkey S1P5, Mouse S1P5, Rat S1P5 and Canine S1P5, respectively. Ozanimod restores the potency with EC50 from 958 nM for mS1P5 to 6.7 nM for mS1P5_A120T to closely mirror the EC50 for hS1P5 of 8.6 nM by mutating the alanine in the mouse sequence. Ozanimod has binding affinity with Ki values of 2.0 nM, 59.9 nM and 5.6 nM forhS1P5, mS1P5 and mS1P5 _A120T, respectively. Ozanimod has saturation binding of [3H]-ozanimod to hS1P5, and mS1P5_A120T with KD values of 6.56 nM, 7.35 nM, respectively and also has saturation binding for A971432 to S1P5D valueof 8.75 nM.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

RPC-1063 | RPC1063

Similar Products

  • RP101988 [orb1744230]

    418.45

    C23H22N4O4

    50 mg, 100 mg, 25 mg
  • RP101442 [orb1744231]

    1306761-08-9

    402.45

    C23H22N4O3

    50 mg, 100 mg, 25 mg
  • RP-101075 [orb1985345]

    1306760-73-5

    360.41

    C21H20N4O2

    100 mg, 25 mg, 50 mg
  • RP101988 [orb1818563]

    0.98

    418.45

    C23H22N4O4

    100 mg
  • (R)-Ozanimod hydrochloride [orb3143563]

    1306760-85-9

    440.92

    C23H25ClN4O3

    50 mg, 10 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Protocol Information

Available Sizes

Select a size below

5 mg
$ 160.00
10 mg
$ 230.00
25 mg
$ 430.00
50 mg
$ 680.00
100 mg
$ 980.00
200 mg
$ 1,370.00
500 mg
$ 2,030.00